AKBA Archives - BioTuesdays

Feature

Akebia challenging the status quo in kidney disease

Akebia Therapeutics (NASDAQ: AKBA) is advancing the Nobel Prize-winning science behind hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) through its commercial product, Vafseo, an oral therapy designed...

September 29, 2026

Developments

JASN publishes analysis highlighting favorable outcomes from Akebia’s Phase 3 study

Akebia Therapeutics (NASDAQ: AKBA) has announced the publication of a post-hoc win statistics analysis of all-cause mortality and hospitalization from its global Phase 3 INNO2VATE program in the peer-reviewed Journal of...

May 4, 2026

Markets

Cantor cuts Akebia to neutral from OW; PT to $1 from $6

Cantor Fitzgerald downgraded Akebia Therapeutics (NASDAQ:AKBA) to “neutral” from “overweight” and slashed its price target to $1 from $6 after the company received a complete response letter in response to the NDA for...

March 31, 2022

Markets

Cantor starts Akebia Therapeutics at OW; PT $8

Cantor Fitzgerald launched coverage of Akebia Therapeutics (NASDAQ:AKBA) with an “overweight” rating and $8 price target. The stock closed at $3.41 on March 5. The company’s lead asset, vadadustat, is an oral hypoxia...

March 8, 2021

Markets

Analysts cut Akebia Therapeutics PT but maintain buy ratings

Analysts for BTIG and H.C. Wainwright reduced their price targets for Akebia Therapeutics (NASDAQ:AKBA) to $6 and $10, respectively, but maintained their “buy” ratings after the company announced top-line results for...

September 4, 2020

Developments

Akebia vadadustat being evaluated for COVID-19-related acute respiratory distress syndrome

Akebia Therapeutics’ (NASDAQ:AKBA) vadadustat is being evaluated in an investigator-sponsored study as a potential therapy to prevent and lessen the severity of COVID-19-related acute respiratory distress syndrome...

July 14, 2020

Developments

Akebia reports positive topline data from Phase 3 vadadustat studies

Akebia Therapeutics (NASDAQ:AKBA) reported positive topline data from two Phase 3 studies of vadadustat for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. The first study...

May 6, 2020

Developments

Akebia Therapeutics vadadustat meets primary endpoint in two Phase 3 trials

Akebia Therapeutics (NASDAQ:AKBA) vadadustat met its primary endpoint in two pivotal Phase 3 clinical trials for anemia due to chronic kidney disease (CKD). The trials compared the safety and efficacy of vadadustat to...

March 13, 2019

Tag - AKBA

Akebia challenging the status quo in kidney disease

JASN publishes analysis highlighting favorable outcomes from Akebia’s Phase 3 study

Cantor cuts Akebia to neutral from OW; PT to $1 from $6

Cantor starts Akebia Therapeutics at OW; PT $8

Analysts cut Akebia Therapeutics PT but maintain buy ratings

Akebia vadadustat being evaluated for COVID-19-related acute respiratory distress syndrome

Akebia reports positive topline data from Phase 3 vadadustat studies

Akebia Therapeutics vadadustat meets primary endpoint in two Phase 3 trials

Subscribe